Loading
GT Biopharma
GT Biopharma is a San Francisco company making proteins that switch on a patient's own natural killer cells, a kind of immune cell, and point them at cancer. Its two lead medicines are in early trials in leukaemia and in solid tumours.
Also called: GT Biopharma, Inc.
Overview
GT Biopharma, Inc., of San Francisco, develops Tri-specific Killer Engager (TriKE) fusion proteins, licensed from work led by Jeffrey Miller at the Masonic Cancer Center of the University of Minnesota. Each binds CD16 on natural killer cells, a tumour antigen, and carries IL-15 to drive natural killer cell expansion; the company states its second-generation camelid nanobody TriKEs are 10 to 40 times more potent than the first. On its pipeline page, GTB-3650 (CD33) is in a phase 1 dose-escalation trial in relapsed or refractory CD33-expressing leukaemias and high-risk myelodysplastic syndrome (NCT06594445), and GTB-5550 (B7-H3), given under the skin, dosed its first patient in a phase 1 basket trial in solid tumours in May 2026 (NCT07541573).
Headquarters
San Francisco, CA, US
Scorecard
All companies#509of 1706 companies, score 8
- phase 1/2 +2
- targets +4
- modalities +2
0 approved, 0 in phase 3, 2 earlier, 2 targets, 0 registry studies. Formula on the scorecards page.
Type
Biotech · GTBP
Stage
Public
Website
Products
2Phase 1Tri-specific natural killer cell engager (camelid nanobody)
GTB-3650 is a protein from GT Biopharma that wakes up natural killer cells and points them at leukaemia cells carrying the CD33 marker. It is in a first trial in people whose leukaemia has come back.
Phase 1Tri-specific natural killer cell engager (dual camelid nanobody, subcutaneous)
GTB-5550 is a protein from GT Biopharma, given as an injection under the skin, that wakes up natural killer cells and points them at tumour cells carrying the B7-H3 marker. It is in a first trial in several solid tumours.
Notes
- The October 2026 S-1 describes the TriKE platform and the University of Minnesota trial agreements but names no candidate; candidates, phases and trial numbers were read on the company's pipeline page on 4 November 2026. Neither trial has an OnCo record.
Connected
6fronts
technologies
targets
drugs
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
gtbiopharma.com · 2
sec.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/